GlassScriptPhysician profile
Jose L Campos
NPI 1245288034
$1,436.23
in general payments reported to CMS, 2019-2025
19 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.90 · 2021: $71.65 · 2022: $126 · 2023: $174 · 2024: $663 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $188.26 | 2024-2025 | Otezla, Repatha, Repatha |
| Verrica Pharmaceuticals INC. | $183.55 | 2024-2025 | Ycanth |
| Astrazeneca Pharmaceuticals LP | $157.30 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $118.27 | 2019-2025 | Gardasil 9, M-M-R II, Rotateq |
| Regeneron Healthcare Solutions, INC. | $115.49 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.98 | 2019-2023 | Jardiance |
| Exact Sciences Corporation | $91.90 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $69.40 | 2023-2024 | Gvoke Hypopen |
| Lilly USA, LLC | $68.71 | 2023-2025 | Mounjaro, Jardiance |
| Boston Scientific Corporation | $62.72 | 2024 | Intracept |
| Novo Nordisk INC | $49.15 | 2021-2025 | |
| Abbott Laboratories | $47.52 | 2022-2024 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $36.34 | 2021 | |
| Abbvie INC. | $34.78 | 2025 | |
| Hologic Sales and Service, LLC | $24.73 | 2025 | Aptima |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $22.52 | 2025 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $21.05 | 2024 | Rexulti |
| Dexcom, INC. | $18.25 | 2025 | Dexcom G6 Transmitter |
| Qiagen, LLC | $17.31 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Campos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.